In order to gain more than this they would of needed to use all dialysates on the market as each contain different chemical properties and would not get the same test results therefore would not be approvalable other than just their dialsate for safety and clinical trial results.This would be the same as getting a drug approved and switching to different chemicals after the drug was approved,which could never happen or the fda would ban the drug.The seeking alpha article today is not even close to being correct.
Initially, I too had this concern; however, upon further DD, there is no evidence to support this assumption. The Cruise trials were run at no less than 47 different trial sites; possibly more. There is no indication that every trial site was required to use only citrapure as the dialyzate. There is also no indication that every trial site was a DaVita dialysis center. This is unlikely in that DaVita was not listed as a collaborator in the study. So I submit that your concerns may have been incorporated into the overall design of the study. Clinical Trils.gov listed no limitations on the source or type of dialyzate to be used in the study so I submit that this was not a constant in order to increase the span of useable dialyzates. While complexing SFP with the citrate anion is necessary to solubilize SFP, there is no evidence that it requires citrapure as the vehicle for delivery. This does not mean that my assumptions are correct either; however, if citrapure was a requirement of the trial it would have been indicated as such.
Seeking alpha writer has assumed Rockwell will get 100% of the market when in reality it remains at about 28% and will stay there for a long time.Fresencius controls about 50% of the dialysis market and manufacturers their own dialysate for 2,100 clinics in the U.S. and has no intention on any change.Rockwell has a very long wait for for approval and several years to obtain any more market share as smaller clinics are closing due to Obamacare and cuts in reimbursements.Wasting your money paying over fair value being in the six dollar range.